Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer

RecruitingOBSERVATIONAL

Enrollment

3,000

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Prostate CancerCastrate Resistant Prostate CancerBRCA Mutation

Interventions

DRUG

Olaparib

Olaparib given according the clinical practice to BRCA positive mCRPC patients

Trial Locations (2)

RECRUITING

Sabrina Rossetti, Napoli

RECRUITING

Orazio Caffo, Trento

All Listed Sponsors

lead

Santa Chiara Hospital

OTHER